Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes in vitro and in vivo

Cancer Research

Volumn 76, Issue 3, 2016, Pages 652-663

  Yue, Peibin ^a   Lopez Tapia, Francisco ^a,b   Paladino, David ^a   Li, Yifei ^c   Chen, Chih Hong ^c   Namanja, Andrew T ^c   Hilliard, Tyvette ^a   Chen, Yuan ^c   Tius, Marcus A ^a,b   Turkson, James ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN SH2; SH4 54; SH5 07; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; HYDROXAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DNA BINDING; PROTEIN EXPRESSION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; GENETIC TRANSFECTION; MALE; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BENZOATES; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; HYDROXAMIC ACIDS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84958214806     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3558     Document Type: Article

References (46)

1. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
2. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11:595-6.
3. Yu H, Jove R. The STATS of Cancer-New molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
4. Yue P, Turkson J. Targeting Stat3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56.
5. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signaling for human diseases. Nat Rev Drug Discov 2013;12:611-29.
6. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
7. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
8. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
9. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
10. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for Stat3. Nat Rev Cancer 2009;9:798-809.
11. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial Stat3 supports Ras-dependent oncogenic transformation. Science 2009;324:1713-6.
12. Siddiquee K, Glenn M, Gunning P, Katt WP, Zhang S, Schroeck C, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007;2:787-98.
13. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence H, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007;104:7391-6.
14. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel smallmolecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 2010;79: 1398-409.
15. Zhang X, Yue P, Page BDG, Li T, Zhao W, Namanja A, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
16. Chen J, Bai L, Bernard D, Nikolovska-Coleska Z, Gomez C, Zhang J, et al. Structure-based design of conformationally constrained, cell-permeable Stat3 inhibitors. ACS Med Chem Lett 2010;1:85-9.
17. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, et al. A novel small molecule, LLL12, inhibits Stat3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010;12:39-50.
18. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, et al. Novel Stat3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010;70: 2445-54.
19. Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, et al. A novel inhibitor of Stat3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res 2013;73:1922-33.
20. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004;3: 261-9.
21. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J Biol Chem 2001;276:45443-55.
22. Coleman DR IV, Ren Z, Mandal PK, Cameron AG, Dyer GA, Muranjan S, et al. Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a High-Affinity Peptide Inhibitor. J Med Chem 2005;48:6661-70.
23. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005;102:4700-5.
24. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
25. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
26. Mora LB, Buettner R, Seigne J, Diaz J, AhmadN, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
27. Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012;31:2309-22.
28. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, et al. Requirement for Ras/Rac1-mediated p38 and c-Jun N-Terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 1999;19:7519-28.
29. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R, et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998;18:2545-52.
30. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, et al. Activation of Stat3 in v-Src transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 2000;275:24935-44.
31. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One 2011;6:e19605.
32. Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BDG, Cheng XR, et al. Potent targeting of the Stat3 protein in brain cancer stem cells: A promising route for treating glioblastoma. ACS Med Chem Lett 2013;4: 1102-7.
33. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent anti-Tumor activity. Mol Cancer Ther 2004;3:1533-42.
34. Zhao W, Jaganathan S, Turkson J. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 2010;285:35855-65.
35. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, et al. Design, synthesis, and studies of small molecule Stat3 inhibitors. Bioorg Med Chem Lett 2008;18:391-5.
36. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, et al. Potent and selective phosphopeptidemimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 2011;54:3549-63.
37. Mandal PK, Liao WS, McMurray JS. Synthesis of phosphatase-stable, cellpermeable peptidomimetic prodrugs that target the SH2 domain of Stat3. Org Lett 2009;11:3394-7.
38. Ball S, Li C, Li PK, Lin J. The small molecule, LLL12, inhibits Stat3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 2011;6:e18820.
39. Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, et al. Cryptotanshinone inhibits human glioma cell proliferation by suppressing Stat3 signaling. Mol Cell Biochem 2013;381:273-82.
40. Xu Y, Li X, Zhang S, Shen D, Li H, Wu Y, et al. Targeting Stat3 suppresses growth of U251 cell-derived tumours in nude mice. J Clin Neurosci 2012;19:443-6.
41. Lin GS, Yang LJ, Wang XF, Chen YP, Tang WL, Chen L, et al. Stat3 Tyr705 phosphorylation affects clinical outcome in patientswith newly diagnosed supratentorial glioblastoma. Med Oncol 2014;31:924.
42. Catlett-Falcone R, Landowski TH, OshiroMM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
43. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.
44. Xie TX, WeiD, Liu M, Gao AC, Ali-Osman F, Sawaya R, et al. Stat3 activation regulates the expression ofmatrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23:3550-60.
45. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
46. Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 2012;10: 155-62.